Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.35 |
| ▸ | TK2 | O00142 | 8/20 | 0.33 |
| ▸ | TK1 | P04183 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5151844 | 0.91 | KIF11 (0.54) | KIF11HRH4SLC6A1TK2TK1 | |
| SCHEMBL5148643 | 0.88 | KIF11 (0.51) | KIF11HRH4SLC6A1TK2TK1 | |
| SCHEMBL5147565 | 0.82 | KIF11 (0.40) | KIF11HRH4SLC6A1TK2TK1 | |
| SCHEMBL5150423 | 0.80 | KIF11 (0.43) | KIF11HRH4SLC6A1NPC1PKM | |
| SCHEMBL5147531 | 0.79 | KIF11 (0.42) | KIF11HRH4SLC6A1TK2TK1 | |
| SCHEMBL6557388 | 0.77 | KIF11 (0.40) | KIF11HRH4SLC6A1TK2TK1 | |
| SCHEMBL5151740 | 0.76 | NQO2 (0.39) | KIF11TSHR | |
| SCHEMBL5150392 | 0.74 | KIF11 (0.38) | KIF11HRH4SLC6A1 | |
| SCHEMBL5150384 | 0.74 | KIF11 (0.38) | KIF11HRH4SLC6A1 | |
| SCHEMBL5150660 | 0.73 | KIF11 (0.36) | KIF11HRH4SLC6A1TK2MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179801-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-02-20 | — | — | US | disclosed |
| EP-1392704-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2006-02-22 | — | — | EP | disclosed |
| US-20040248875-A1 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248875-A1 | Cephem compounds | CEP170, C1S, SLC7A1 | KIF11 3495/4885HRH4 330/4885SLC6A1 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.